Thalidomide- and bortezomib-induced neuropathy in multiple myeloma, possibility of treatment of neuropathic pain. Recommendations of the Polish Myeloma Study Group;Polineuropatia wywołana talidomidem i bortezomibem u chorych na szpiczaka mnogiego, możliwości leczenia bólu neuropatycznego. Zalecenia Polskiej Grupy Szpiczakowej

Wspolczesna Onkologia

Volumn 12, Issue 10, 2008, Pages 441-446

  Bilińska, Małgorzata ^a   Usnarska Zubkiewicz, Lidia ^a   Dmoszyńska, Anna ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Uniwersytet Medyczny   (Poland)

Author keywords

Bortezomib; Neuropathy treatment; Thalidomide

Indexed keywords

AMITRIPTYLINE; BORTEZOMIB; DULOXETINE; GABAPENTIN; PLACEBO; PREGABALIN; THALIDOMIDE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; MULTIPLE MYELOMA; NEUROPATHIC PAIN; NEUROPATHY; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; SENSORY NEUROPATHY;

EID: 67149126622     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Hilkens PH, Verweij J, Stoter G, Vecht ChJ, Putten WLJ, van den Bent MJ. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46: 104-8.
2. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53: 828-32.
3. Gao WQ, Dybal N, Shinsky N, et al. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 1995; 38: 30-7.
4. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trials. Pain 2004; 110: 628-38.
5. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E. Gabapentin in the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 1998; 280: 1831-6.
6. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trials. Pain 1999; 83: 85-90.
7. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837-42.
8. Dworkin RH, Corbin AE, Young JP, et al. Pregabalin for the treatment of posherpetic neuralgia. a randomized, placebo-controlled trial. Neurology 2003; 60: 1274-83.
9. Walsh JC. The neuropathy of multiple myeloma. An electrophysiological and histological study. Arch Neurol 1971; 25: 404-14.
10. Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide. Neurology 2007; 69: 573-81.
11. Stillman M, Cata J. Management of chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 2006; 10: 279-87.
12. Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002; 59: 1872-5.
13. Molloy FM, Floeter MK, Syed NA, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001; 24: 1050-7.
14. Laaksonen S, Remes K, Koskela K, Voipio-Pulkki LM, Falck B. Thalidomide therapy and polyneuropathy in myeloma patients. Electromyogr Clin Neurophysiol 2005; 45: 75-86.
15. Hess CW, Hunziker T, Kupfer A, Ludin HP. Thalidomide-induced neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol 1986; 233: 83-9.
16. Ochonisky S, Verroust J, Bastuji-Garon S, Gherardi R, Revuz J. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 66-9.
17. Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 2004; 109: 188-93.
18. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24: 4507-14.
19. Offidani M, Corvatta L, Marconi M, et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 2004; 72: 403-9.
20. Lagueny A, Rommel A, Vignolly B, Taieb A, Vendeaud-Busquet M, Doutre MS, Julien J. Thalidomide neuropathy: an electrophysiologic study. Muscle Nerve 1986; 9: 837-44.
21. Giannini F, Volpi N, Rossi S, Passero S, Fimiani M, Cerase A. Thalidomide-induced neuropathy: a ganglionopathy? Neurology 2003; 60: 877-8.
22. Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients wit multiple myeloma. Eur J Haematol 2005; 74: 212-6.
23. Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004; 79: 875-82.
24. Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin Neurol 2005; 18: 574-80.
25. van den Bent MJ. Prevention of chemotherapy-induced neuropathy: leukemia inhibitory factor. Clin Cancer Res 2005; 11: 1691-3.
26. Cata JP, Weng H-R, Burton AW, Villareal H, Giralt S, Dougherty PM. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007; 8: 296-306.
27. Stubblefield MD, Slovin S, MacGregor-Cortelli B, et al. An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clin Oncol 2006; 18: 410-8.
28. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. NEJM 2003; 348: 2609-17.
29. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113-20.
30. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007; 110: 1042-8.
31. Walter-Croneck A, Dmoszyńska A, Skotnicki A i wsp. Skuteczność i bezpieczeństwo bortezomibu w leczeniu opornego/nawrotowego szpiczaka plazmocytowego - doświadczenia Polskiej Grupy Szpiczakowej. Acta Haematol Pol 2006; 37 suppl. 1: 125-34.
32. Gidal B, Billington R. New and emerging treatment options for neuropathic pain. Am J Manag Care 2006; 12: S269-78.
33. Melzack R. The short - form McGill Pain Questionnaire. Pain 1987; 30: 191-7.
34. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 149-58.
35. Goa KL, Sorkin EM. Gabapentin: review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409-27.
36. Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002; 57: 451-62.
37. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 1997; 121: 1513-22.
38. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995; 45: 1115-21.
39. Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006; 6: 108-13.
40. Frampton JE, Scott LJ. Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs 2004; 64: 2813-20.
41. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004; 63: 2104-10.
42. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005; 115: 254-63.
43. Gomez-Perez FJ, Rull JA, Dies H, Rodriquez-Rivera JG, Gonzalez-Barranco J, Lozano-Castañeda O. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain 1985; 23: 395-400.
44. Max MB, Kishore-Kumar R, Schafer SC, Meister B, Gracely RH, Smoller B, Dubner R. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991; 45: 3-9.
45. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990; 47: 305-12.
46. Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982; 32: 671-3.
47. Watson CPN, Vernich L, Chipman M, Reed K. Nortryptyline versus amitryptyline in postherpetic neuralgia: a randomized trial. Neurology 1998; 51: 1166-71.
48. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389-400.
49. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004; 311: 576-84.
50. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 1991; 14: 309-29.
51. Westanmo AD, Gayken J, Haight R. Duloxetine: a balanced and selective norepinephrine and serotonin reuptake inhibitor. Am J Health Syst Pharm 2005; 62: 2481-90.
52. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109-18.
53. Raffa RB, Friderichs F, Reimann W, Shank RB, Codd EE, Vaught JL. Opioid and non-opioid components independently contribute to the mechanism of action of tramadol, an atypical opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275-85.
54. Osipova NA, Novikoy GA, Beresnev VA, Loseva NA. Analgesic effect of tramadol in cancer patients with chronic pain: a comparison with prolonged action morphine sulfate. Curr Ther Res 1991; 50: 812-21.
55. Preston KL, Jasinski DR, Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend 1991; 27: 7-17.
56. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50: 1842-6.